Skip to main content
Premium Trial:

Request an Annual Quote

MedMira Gets CE Mark for COVID, Flu Combo Assay

NEW YORK — Canadian diagnostics firm MedMira said on Wednesday that it has received CE marking for its Vyra CoV2Flu Antigen Test, a combination assay for SARS-CoV-2 and influenza A and B.

The test uses the company's Rapid Vertical Flow technology, which enables the formation of specific antigen-antibody reactions for the capture of biomarkers in sample types. It is designed to detect the viruses in a single nasal swab sample.

In late 2022, MedMira received CE marking for the Vyra COVID-19 Antigen Test.